Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices

Ginkgo Bioworks (DNA) announced a subcontract of up to $9.4M awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. This initiative is part of the Advanced Research Projects Agency for Health’s Resilient Extended Automatic Cell Therapies program. Ginkgo is eligible to receive up to $9.4M for its work across the program. Through this collaboration, Ginkgo will leverage its capabilities in mammalian cell engineering and induced pluripotent stem cell engineering to create cells that produce and deliver therapeutic molecules-such as hormones-and/or monitor the disease status.